ZLNA.OL Zelluna ASA
- Market cap
- NOK 567M
- P/E
- -
- P/B
- 4.86x
- ROE
- -75.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ZLNA.OL undervalued?
Graham numberThe Graham number of Zelluna ASA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zelluna ASA fundamental analysis
No fundamental analysis for Zelluna ASA yet.
Zelluna ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zelluna ASA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid …
Full company profileZelluna ASA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zelluna ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 53.0K | 0.00 | 0.00 |
| Operating Income | -164M | -184M | -216M | -110M | -144M | -80.4M |
| EBITDA | - | -181M | -213M | -101M | -136M | -76.2M |
| Net Income | -165M | -168M | -189M | -105M | -141M | -80.1M |
| EPS | -48 | -49 | -55 | -31 | -5.36 | -2.72 |
| Balance Sheet | ||||||
| Total Assets | 656M | 510M | 349M | 50.4M | 104M | 114M |
| Total Liabilities | 62.4M | 60.3M | 69.6M | 14.4M | 17.6M | 7.96M |
| Shareholders' Equity | 593M | 449M | 279M | 36.0M | 85.9M | 106M |
| Cash & Short-term Investments | 574M | 430M | 270M | 32.4M | 83.5M | 86.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -126M | -168M | -190M | -100.0M | -149M | -97.3M |
| Capital Expenditure | 85.0K | 195K | 25.0K | 10.4M | 359K | 0.00 |
| Free Cash Flow | -126M | -168M | -190M | -163M | -149M | -97.3M |
| Ratios | ||||||
| ROE | -27.8% | -37.3% | -67.7% | -291.8% | -163.9% | -75.8% |
| ROA | -25.1% | -32.9% | -54.2% | -208.6% | -135.9% | -70.5% |
| Net Profit Margin | - | - | - | -198,418.9% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zelluna ASA dividends
Zelluna ASA has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Apr 1, 2025.
Who owns Zelluna ASA
- Insiders 40.60%
- Institutions 15.72%
- Public & others 43.68%
- Shares outstanding 29.9M
- Free float 13.4M
Zelluna ASA company profile
- Company name
- Zelluna ASA
- Ticker
- ZLNA.OL
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- Oslo Cancer Cluster Innovation Park, Oslo, Norway, 0379
- Phone
- 47 41 38 00 80
- Website
- zelluna.com
About Zelluna ASA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.
Zelluna ASA management
9- Mr. Namir Hassan Ph.D.Chief Executive Officer
- Mr. Geir Christian Melen MScChief Financial Officer · born 1965
- Mr. Anders Holm Ph.D.Chief Operating Officer & Head of Business Development
- Ms. Emilie Gauthy Ph.D.Chief Technology Officer
- Ms. Luise Weigand Ph.D.Chief Scientific Officer
- Ms. Julia Ino Ph.D.Head of Project Management & Clinical Project Manager
- Mr. Anders TuvCo-Founder & Chairman
- Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D.Chief Medical Officer
- Orla Mc CallionHead of Regulatory Affairs & QA